Head and Neck Neoplasms: Clinical Trials

2,935 trials for Head and Neck Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1077 completed, 510 unknown, 496 recruiting, 314 terminated. 2935 Phase 2, 549 Phase 1, 108 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22935Completed 1077, Unknown 510, Recruiting 496, Terminated 314, Active not recruiting 234, Not yet recruiting 186, Withdrawn 98, Enrolling by invitation 10, Suspended 10
Phase 1549Completed 200, Recruiting 105, Terminated 81, Unknown 69, Active not recruiting 46, Not yet recruiting 22, Withdrawn 20, Enrolling by invitation 4, Suspended 2
Phase 3108Completed 28, Recruiting 26, Unknown 21, Terminated 11, Active not recruiting 9, Not yet recruiting 7, Withdrawn 5, Suspended 1

Follow Head and Neck Neoplasms: new trials by email Literature Review of Head and Neck Neoplasms trials Research Report on Head and Neck Neoplasms

Trials (filtered) newest first · largest first

All 2,935 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
Phase 2WithdrawnActuate Therapeutics Inc.2030-12-182022-02-22
The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck
Nutrition counseling, Fresubin Supportan - Head &Amp;Amp; Neck Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingAnna Arthur, PhD152027-06-012026-08-07
Chemo-embolization for Head and Neck Cancer
Cisplatin - SCCHN, Squamous Cell Carcinoma
Phase 2WithdrawnUniversity of Alabama at Birmingham2027-05-012025-04-27
A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy
Colchicine, Placebo - Head and Neck Cancer
Phase 2Not yet recruitingM.D. Anderson Cancer Center2502027-03-012026-10-05
Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer
Stereotactic body radiation treatment (SBRT) - Esophageal Cancer
Phase 2Not yet recruitingAHS Cancer Control Alberta222027-03-012026-10-28
Sac-TMT in Salivary Gland Cancers
Sacituzumab Tirumotecan (Sac-TMT) - Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary Gland
Phase 2Not yet recruitingLatin American Cooperative Oncology Group642027-03-012026-11-10
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial
FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab - Gastroesophageal Adenocarcinoma
Phase 2Not yet recruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre1842027-01-012026-07-10
Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction Immunochemotherapy
Becotatug Vedotin (MRG003), Pucotenlimab - Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 2Not yet recruitingSun Yat-sen University222027-01-012026-11-04
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma
Phase 2Not yet recruitingVanderbilt-Ingram Cancer Center202026-12-312026-09-23
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer
Phase 2Not yet recruitingWashington University School of Medicine122026-12-312026-10-21
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 2Not yet recruitingWashington University School of Medicine402026-12-312026-10-28
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2WithdrawnDana-Farber Cancer Institute2026-12-012026-10-08
Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse
Placebo, Ketamine Topical - Head and Neck Cancer
Phase 2Not yet recruitingUniversity of Oklahoma622026-12-012026-10-16
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Phase 2Not yet recruitingFred Hutchinson Cancer Center502026-12-012026-09-17
Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Cisplatin, Epinephrine injection, Laryngeal Biopsy - Laryngeal Squamous Cell Carcinoma
Phase 2RecruitingUniversity of Miami202026-12-012026-08-26
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Phase 2Not yet recruitingSun Yat-sen University2982026-12-012026-10-27
A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
Sacituzumab Tirumotecan - Esophageal Squamous Cell Carcinoma
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital302026-12-012026-11-16
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
[225Ac]Ac-FL-261 - Solid Tumor, NSCLC
Phase 1 / Phase 2RecruitingFull-Life Technologies UK Limited2082026-12-012026-11-16
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingWashington University School of Medicine452026-11-302026-11-03

Showing 20 of 2935. Sign in to see all of them.

Narrower conditions

Squamous Cell Carcinoma of Head and Neck (903)  ·  Esophageal Neoplasms (614)  ·  Esophageal Squamous Cell Carcinoma (355)  ·  Nasopharyngeal Carcinoma (284)  ·  Stomach Neoplasms (220)  ·  Carcinoma, Non-Small-Cell Lung (202)  ·  Thyroid Neoplasms (192)  ·  Carcinoma, Squamous Cell (140)  ·  Neoplasm Metastasis (138)  ·  Oropharyngeal Neoplasms (136)  ·  Neoplasms (133)  ·  Adenocarcinoma Of Esophagus (130)  ·  Colorectal Neoplasms (114)  ·  Melanoma (114)

Broader conditions

Neoplasms by Site (2918)  ·  Neoplasms (2802)  ·  Neoplasms by Histologic Type (1813)  ·  Neoplasms, Glandular and Epithelial (1784)  ·  Carcinoma (1698)  ·  Carcinoma, Squamous Cell (1160)  ·  Digestive System Diseases (1044)  ·  Gastrointestinal Diseases (1024)  ·  Digestive System Neoplasms (1008)  ·  Gastrointestinal Neoplasms (969)  ·  Esophageal Diseases (876)  ·  Stomatognathic Diseases (728)  ·  Otorhinolaryngologic Diseases (566)  ·  Otorhinolaryngologic Neoplasms (533)

Interventions

Cisplatin (544)  ·  Radiotherapy (284)  ·  pembrolizumab (251)  ·  Paclitaxel (240)  ·  Carboplatin (221)  ·  Fluorouracil (216)  ·  Docetaxel (198)  ·  Cetuximab (194)  ·  Radiotherapy, Intensity-Modulated (132)  ·  Nivolumab (109)  ·  Drug Therapy (95)  ·  Capecitabine (92)  ·  Oxaliplatin (90)  ·  Radiation (85)  ·  toripalimab (78)

Sponsors

Sun Yat-sen University (128)  ·  National Cancer Institute (NCI) (122)  ·  M.D. Anderson Cancer Center (66)  ·  Memorial Sloan Kettering Cancer Center (63)  ·  Fudan University (60)  ·  Dana-Farber Cancer Institute (47)  ·  Washington University School of Medicine (30)  ·  University of Chicago (29)  ·  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (28)  ·  Zhejiang Cancer Hospital (28)  ·  University of Michigan Rogel Cancer Center (27)  ·  Tianjin Medical University Cancer Institute and Hospital (26)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (25)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (25)  ·  West China Hospital (21)

Countries

United States (1275)  ·  China (861)  ·  France (199)  ·  Canada (160)  ·  Spain (146)  ·  United Kingdom (138)  ·  South Korea (134)  ·  Germany (108)  ·  Taiwan (108)  ·  Italy (105)  ·  Belgium (93)  ·  Australia (90)  ·  Netherlands (68)  ·  Japan (62)  ·  Singapore (58)

Top investigators

Aminah Jatoi, MD (8)  ·  Douglas Adkins, M.D. (8)  ·  Yue He, M.D. (8)  ·  David H. Ilson, MD, PhD (7)  ·  Douglas R Adkins, M.D. (7)  ·  Nancy Lee, MD (7)  ·  A. Dimitrios Colevas, MD (6)

Results publications

PMID 25057165, PMID 22646630, PMID 37934000, PMID 26313683, PMID 26884585, PMID 30207593, PMID 31150573, PMID 33720067, PMID 34503735, PMID 35623069, PMID 36990609, PMID 39532605, PMID 39584361, PMID 40341199, PMID 41044356, PMID 19097774, PMID 19564532, PMID 21183517, PMID 25081901, PMID 25979390, PMID 26808342, PMID 27240885, PMID 28434660, PMID 28742685, PMID 28797458, PMID 31838007, PMID 32017652, PMID 32665297, PMID 32852531, PMID 33720068, PMID 33963014, PMID 34341578, PMID 34937871, PMID 35046059, PMID 35355438, PMID 37195667, PMID 37496366, PMID 37580352, PMID 37816266, PMID 40086048, PMID 40855191, PMID 41309527, PMID 41531940, PMID 42568612, PMID 10235156, PMID 10444409, PMID 10811668, PMID 11208820, PMID 11224527, PMID 11240232

NIH funding

2023 (29), 2016 (19), U10CA032102 (19), 2019 (16), 2017 (15), 2015 (13), U10CA021115 (12), N01CM62201 (10), P30CA006516 (10), U10CA180868 (10), 2025 (9), P30CA016672 (9), 2014 (8), 2018 (8), P30CA014599 (8)